Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE

Jeffrey A. Kline, Donald M. Yealy

Research output: Contribution to journalShort survey

2 Scopus citations


The EINSTEIN-PE trial showed that rivaroxaban has equal efficacy and a lower rate of bleeding than coumarins in the treatment of acute pulmonary embolism. We anticipate regulatory and consumer acceptance for rivaroxaban, representing the first new anticoagulant treatment for venous thromboembolism since the introduction of warfarin compounds 50 years ago.

Original languageEnglish (US)
Pages (from-to)378-380
Number of pages3
JournalNature Reviews Cardiology
Issue number7
StatePublished - Jul 1 2012


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this